Csop Hang Seng Tech Index ETF(03033.HK) Rose 0.68% to 4.768
Newtimespace News, as of 09:44 on May 19, Csop Hang Seng Tech Index ETF(03033.HK) was quoted at HKD 4.768, up 0.68%. The ETF opened at HKD 4.734, with a high of HKD 4.778 and a low of HKD 4.718. The latest Net Asset Value (NAV) per unit is HKD 4.743, with a premium rate of -0.15%. The asset size is approximately HKD 84.437 billion.
Csop Hang Seng Tech Index ETF(03033.HK) tracks the Hang Seng Tech Index, which is compiled and published by Hang Seng Indexes Company Limited. This index is the first technology sector-themed index in the Hong Kong market, aiming to reflect the performance of the largest technology companies (i.e., tech giants) listed on The Stock Exchange of Hong Kong. Its constituent stocks cover cutting-edge technology fields such as the Internet, fintech, cloud computing, e-commerce, and digital businesses, collectively embodying the growth and innovative vitality of Hong Kong's technology sector.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- VSING (08292.HK): Proposes Acquisition of Equity Interest in Golfzon Hong Kong to Build "Technology + Sports + Social" Entertainment Experience
- HK SH ALLIANCE (01001.HK): Subsidiary Unsuccessful in Tender for Tsing Yi Advanced Construction Industry Building Project
- BAIYUNSHAN PH (00874.HK): Dexamethasone Sodium Phosphate Injection (1ml:5mg) of Controlled Subsidiary Passes Generic Consistency Evaluation
- CI FIN TECH GP (08029.HK): Executive Director Wang Qiang Appointed Chairman of the Board; Zheng Meicheng Appointed Vice-chairwoman
- Shaanxi Micot Pharmaceutical Technology Co., Ltd (02335.HK): Phase II Clinical Study of Dual-Function Antithrombotic Candidate MT1002 for Anticoagulation in Haemodialysis Completes First Patient Enrolment